Literature DB >> 28197743

The Impact of Therapeutic Antibodies on the Management of Digestive Diseases: History, Current Practice, and Future Directions.

M Anthony Sofia1, David T Rubin2.   

Abstract

The development of therapeutic antibodies represents a revolutionary change in medical therapy for digestive diseases. Beginning with the initial studies that confirmed the pathogenicity of cytokines in inflammatory bowel disease, the development and application of therapeutic antibodies brought challenges and insights into their potential and optimal use. Infliximab was the first biological drug approved for use in Crohn's disease and ulcerative colitis. The lessons learned from infliximab include the importance of immunogenicity and the influence of pharmacokinetics on disease response and outcomes. Building on this foundation, other therapeutic antibodies achieved approval for inflammatory bowel disease and many more are in development for several digestive diseases. In this review, we reflect on the history of therapeutic antibodies and discuss current practice and future directions for the field.

Entities:  

Keywords:  Adalimumab; Inflammatory bowel disease; Infliximab; Therapeutic antibodies; Therapeutic drug monitoring; Tumor necrosis factor alpha

Mesh：

Substances：

Year:  2017        PMID： 28197743     DOI： 10.1007/s10620-017-4479-0

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN： 0163-2116            Impact factor:   3.199


  113 in total

1.  Switching Between Infliximab Originator and Biosimilar in Paediatric Patients with Inflammatory Bowel Disease. Preliminary Observations.

Authors:  J Sieczkowska; D Jarzębicka; A Banaszkiewicz; A Plocek; A Gawronska; E Toporowska-Kowalska; G Oracz; M Meglicka; J Kierkus
Journal:  J Crohns Colitis       Date:  2015-12-30       Impact factor: 9.071

2.  Expression of matrix metalloproteinases-2 and -9 in intestinal tissue of patients with inflammatory bowel diseases.

Authors:  Q Gao; M J W Meijer; F J G M Kubben; C F M Sier; L Kruidenier; W van Duijn; M van den Berg; R A van Hogezand; C B H W Lamers; H W Verspaget
Journal:  Dig Liver Dis       Date:  2005-08       Impact factor: 4.088

3.  Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial.

Authors:  Walter Reinisch; William J Sandborn; Daniel W Hommes; Geert D'Haens; Stephen Hanauer; Stefan Schreiber; Remo Panaccione; Richard N Fedorak; Mary Beth Tighe; Bidan Huang; Wendy Kampman; Andreas Lazar; Roopal Thakkar
Journal:  Gut       Date:  2011-01-05       Impact factor: 23.059

4.  Serum albumin concentration: a predictive factor of infliximab pharmacokinetics and clinical response in patients with ulcerative colitis.

Authors:  A A Fasanmade; O J Adedokun; A Olson; R Strauss; H M Davis
Journal:  Int J Clin Pharmacol Ther       Date:  2010-05       Impact factor: 1.366

5.  Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial.

Authors:  Stephen B Hanauer; Brian G Feagan; Gary R Lichtenstein; Lloyd F Mayer; S Schreiber; Jean Frederic Colombel; Daniel Rachmilewitz; Douglas C Wolf; Allan Olson; Weihang Bao; Paul Rutgeerts
Journal:  Lancet       Date:  2002-05-04       Impact factor: 79.321

6.  Expression of pro-inflammatory cytokines by TCR alpha beta+ and TCR gamma delta+ T cells in an experimental model of colitis.

Authors:  S J Simpson; G A Holländer; E Mizoguchi; D Allen; A K Bhan; B Wang; C Terhorst
Journal:  Eur J Immunol       Date:  1997-01       Impact factor: 5.532

7.  MAdCAM-1 expressed in chronic inflammatory liver disease supports mucosal lymphocyte adhesion to hepatic endothelium (MAdCAM-1 in chronic inflammatory liver disease).

Authors:  A J Grant; P F Lalor; S G Hübscher; M Briskin; D H Adams
Journal:  Hepatology       Date:  2001-05       Impact factor: 17.425

8.  Comparative Effectiveness of Infliximab and Adalimumab in Crohn's Disease and Ulcerative Colitis.

Authors:  Ashwin N Ananthakrishnan; Andrew Cagan; Tianxi Cai; Vivian S Gainer; Stanley Y Shaw; Guergana Savova; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Katherine P Liao; Shawn N Murphy
Journal:  Inflamm Bowel Dis       Date:  2016-04       Impact factor: 5.325

9.  Combination therapy with infliximab and azathioprine is superior to monotherapy with either agent in ulcerative colitis.

Authors:  Remo Panaccione; Subrata Ghosh; Stephen Middleton; Juan R Márquez; Boyd B Scott; Laurence Flint; Hubert J F van Hoogstraten; Annie C Chen; Hanzhe Zheng; Silvio Danese; Paul Rutgeerts
Journal:  Gastroenterology       Date:  2014-02       Impact factor: 22.682

10.  Efficacy and Safety of the Biosimilar Infliximab CT-P13 Treatment in Inflammatory Bowel Diseases: A Prospective, Multicentre, Nationwide Cohort.

Authors:  Krisztina B Gecse; Barbara D Lovász; Klaudia Farkas; János Banai; László Bene; Beáta Gasztonyi; Petra Anna Golovics; Tünde Kristóf; László Lakatos; Ágnes Anna Csontos; Márk Juhász; Ferenc Nagy; Károly Palatka; Mária Papp; Árpád Patai; Lilla Lakner; Ágnes Salamon; Tamás Szamosi; Zoltán Szepes; Gábor T Tóth; Áron Vincze; Balázs Szalay; Tamás Molnár; Péter L Lakatos
Journal:  J Crohns Colitis       Date:  2015-12-10       Impact factor: 9.071
View more
  2 in total

1.  Recent advances in the treatment of C. difficile using biotherapeutic agents.

Authors:  Vo Van Giau; Hyon Lee; Seong Soo A An; John Hulme
Journal:  Infect Drug Resist       Date:  2019-06-10       Impact factor: 4.003

Review 2.  Proteomics and Lipidomics in Inflammatory Bowel Disease Research: From Mechanistic Insights to Biomarker Identification.

Authors:  Bjoern Titz; Raffaella M Gadaleta; Giuseppe Lo Sasso; Ashraf Elamin; Kim Ekroos; Nikolai V Ivanov; Manuel C Peitsch; Julia Hoeng
Journal:  Int J Mol Sci       Date:  2018-09-15       Impact factor: 5.923
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.